In this March 2026 edition of Drugs.com Monthly Update Podcast, learn about the FDA's latest approvals, including Wegovy HD for obesity, Icotyde for plaque psoriasis, Sotyktu for psoriatic arthritis, and Awiqli for type 2 diabetes.

Wegovy HD (semaglutide): A new high-dose option for adults managing obesity, showing significant weight loss in clinical trials.

Icotyde (icotrokinra): The first oral IL-23 blocker approved to treat moderate-to-severe plaque psoriasis, providing a new oral treatment choice.

Sotyktu (deucravacitinib): An oral TYK2 inhibitor now approved for treating active psoriatic arthritis, addressing inflammation with a convenient dosing regimen.

Awiqli (insulin isodec): The first once-weekly basal insulin for adults with type 2 diabetes.

Chapters:

• (00:21) - Intro
• (01:00) - Wegovy HD
• (02:10) - Icotyde
• (03:12) - Sotyktu
• (03:53) - Awiqli
• (04:32) - Outro

• X, Facebook, Youtube
• Sign up to our newsletters
• Download the app

In this February 2026 edition of Drugs.com Monthly Update Podcast, learn about new options in weight management, type 2 diabetes, and lung cancer. Discover Eli Lilly's Zepbound KwikPen for simplified dosing in obesity management, the upcoming launch of the oral Ozempic pill for diabetes by Novo Nordisk, IBSA Pharma’s oral film formulation of sildenafil for erectile dysfunction called Vybrique, and the monthly Rybrevant Faspro injection for advanced NSCLC.

• Zepbound KwikPen (tirzepatide): A new multidose Zepbound pen supplying 4 fixed weekly doses in one pen
• Ozempic pill (semaglutide): Discover the upcoming once-daily oral option for adults with type 2 diabetes to manage blood sugar and cardiovascular risks.
• Rybrevant Faspro (amivantamab and hyaluronidase-lpuj): Explore the benefits of a simplified, monthly injectable regimen for EGFR-mutated NSCLC.
• Dupixent (dupilumab): The first approved therapy for allergic fungal rhinosinusitis, reducing the need for systemic steroids.
• Vybrique (sildenafil): A new oral film formulation of sildenafil for erectile dysfunction.
• Calquence + Venetoclax (acalabrutinib combination): This new all-oral regimen provides a targeted therapy for CLL, improving patient outcomes with a non-chemo approach.

Chapters:

• (00:00) - Intro
• (00:20) - Overview

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

In our latest episode, we cover the latest approval of Darzalex Faspro for multiple myeloma, age-related near vision loss, and a rare genetic disorder affecting children. We also discuss an extension to the use of Nexplanon, a long-acting birth control, and a simpler transition for those moving from injected to inhaled insulin.

• Darzalex Faspro (daratumumab and hyaluronidase-fihj) a new approval for use in combination with standard treatments for adults with newly diagnosed multiple myeloma.
• Yuvezzi (carbachol and brimonidine tartrate), a novel combination eye drop for presbyopia.
• Zycubo (copper histidinate), the first treatment for Menkes disease in children.
• Nexplanon (etonogestrel), a birth control implant with an extension of use for up to five years.
• Afrezza (insulin human), an inhaled insulin, with updated dosing guidance.

Chapters

• (00:00) - Intro
• (00:21) - Overview
• (00:47) - Darzalex
• (02:13) - Yuvezzi
• (03:06) - Zycubo
• (03:50) - Nexplanon
• (04:35) - Afrezza
• (05:09) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

This month, discover the Wegovy tablet, the first oral GLP-1 weight loss medication to be approved, Myqorzo's long-awaited treatment for obstructive hypertrophic cardiomyopathy, and several other exciting new FDA approvals. Explore these key stories and more in our December 2025 round-up.

• Wegovy (semaglutide) tablet, the first oral GLP-1 for weight loss, with significant efficacy in patient trials.
• Myqorzo (aficamten), a long-awaited and major addition to obstructive hypertrophic cardiomyopathy treatment that improves exercise capacity.
• Exdensur (depemokimab-ulaa), a new long-term, add-on treatment for severe eosinophilic asthma with twice-yearly injections.
• Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor whose approval has been extended to include chronic lymphocytic leukemia and small lymphocytic lymphoma.
• Lerochol (lerodalcibep-liga), a third-generation, PCSK9 inhibitor for high cholesterol self-administered via a monthly injection.
• Breyanzi (lisocabtagene maraleucel), a CAR T cell therapy with extended approval to include relapsed or refractory marginal zone lymphoma.

Chapters

• (00:00) - Intro
• (00:22) - Overview
• (00:34) - Wegovy
• (01:16) - Myqorzo
• (02:07) - Exdensur
• (02:56) - Jaypirca
• (03:31) - Lerochol
• (04:09) - Breyanzi
• (04:46) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

In this episode, we explore key FDA approvals from November 2025, including treatments like Keytruda Qlex for bladder cancer, Epkinly for follicular lymphoma, and the long-acting Eylea HD for macular edema. Discover what these developments mean for patients and professionals alike.

• Keytruda (pembrolizumab), approved in combination with Padcev as neoadjuvant treatment for adults with muscle-invasive bladder cancer ineligible for cisplatin-containing chemotherapy, demonstrating a 60% reduction in event-free survival events.
• Epkinly (epcoritamab-bysp) plus rituximab and lenalidomide, approved for adults with relapsed or refractory follicular lymphoma, showing a 79% reduction in disease progression risk through T-cell engagement with malignant B-cells.
• Darzalex Faspro (daratumumab and hyaluronidase-fihj), now the first and only approved treatment for patients with high-risk smoldering multiple myeloma, significantly slowing disease progression.
• Eylea HD (aflibercept ophthalmic), approved for macular edema following retinal vein occlusion with extended up to every 8-week dosing after initial treatment, maintaining visual acuity with less frequent administration.
• Caplyta (lumateperone), newly approved as an add-on therapy for adults with major depressive disorder, enhancing outcomes when used alongside existing antidepressants.

Chapters:

• (00:00) - Intro
• (00:37) - Discussion points
• (00:47) - Keytruda
• (01:20) - Epkinly
• (02:10) - Darzalex
• (02:47) - Eylea HD
• (03:14) - Caplyta
• (03:43) - Key takeaways
• (04:02) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

This month’s update dives into significant FDA approvals affecting key therapeutic areas. Discover groundbreaking treatments like Novo Nordisk’s Rybelsus for cardiovascular risk reduction in diabetes, and innovative solutions like Gazyva for lupus nephritis. Tune in to learn how these advancements could impact patient management and outcomes.

• Rybelsus (semaglutide): Exploring its new role in cardiovascular risk reduction for adults with type 2 diabetes.
• Zoryve (roflumilast): A breakthrough steroid-free topical treatment for eczema in young children.
• Gazyva (obinutuzumab): Approved for lupus nephritis, offering new hope for managing this serious kidney ailment.
• Lynkuet (elinzanetant): A hormone-free option for alleviating hot flashes due to menopause.
• Lasix ONYU (furosemide injection): Introducing an at-home infusion method for heart failure patients dealing with edema.
• Jascayd (nerandomilast): A new approval to combat the progression of idiopathic pulmonary fibrosis.

Chapters:

• (00:00) - Intro
• (00:40) - Rybelsus
• (01:36) - Zoryve Cream
• (02:17) - Gazyva
• (02:51) - Lynkuet
• (03:01) - Lasix ONYU
• (03:44) - Jascayd
• (04:16) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

Discover the latest in pharmaceutical advancements with our September 2025 roundup. We're covering newly approved treatments like Rhapsido for chronic spontaneous urticaria, Palsonify for acromegaly, and Inluriyo for ESR1-mutated breast cancer. Learn about groundbreaking therapies, their impacts on patient care, and what these mean for healthcare professionals and patients alike.

• Rhapsido (remibrutinib) for the management of difficult chronic spontaneous urticaria in adults still experiencing symptoms despite antihistamine therapy.
• Palsonify (paltusotine) introduces a groundbreaking once-daily oral option for acromegaly, offering rapid control of growth hormone levels.
• Inluriyo (imlunestrant), a significant development for treating ESR1-mutated breast cancer in patients who have experienced disease progression after endocrine therapy.
• Forzinity (elamipretide hydrochloride) provides hope for children with Barth syndrome by improving muscle strength through mitochondrial support.
• Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), a quicker subcutaneous option for pembrolizumab administration, simplifying immunotherapy for melanoma and non-small cell lung cancer patients.

Chapters

• (00:25) - Intro
• (00:51) - Rhapsido
• (01:47) - Palsonify
• (02:48) - Inluriyo
• (03:33) - Forzinity
• (04:09) - Keytruda Qlex
• (04:45) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app

August 2025 brought significant advances in therapies for conditions ranging from metabolic liver disease to pediatric migraine prevention and beyond. Tune in as we delve into key FDA approvals like Novo Nordisk's Wegovy for MASH, Tonmya for fibromyalgia, and Ajovy's pediatric migraine approval, and explore their implications in clinical practice.

• Wegovy (semaglutide) for metabolic liver disease: Now indicated for metabolic dysfunction-associated steatohepatitis (MASH) in adults, offering a new treatment pathway for this progressive liver condition.
• Tonmya (cyclobenzaprine) for fibromyalgia: A potent sublingual treatment, provides hope in managing fibromyalgia's chronic pain and sleep disturbances.
• Ajovy (fremanezumab) for pediatric migraines: The first anti-CGRP therapy approved for migraine prevention in children, opening new avenues for managing this debilitating condition.
• Repatha (evolocumab) for cardiovascular risk: Expanded use in adults at risk for major cardiovascular events, even absent diagnosed cardiovascular disease.
• Brinsupri (brensocatib) for bronchiectasis: Provides a novel oral option for reducing flares in non-cystic fibrosis bronchiectasis, promising symptom relief.

Chapters:

• (00:00) - Intro
• (00:41) - Wegovy
• (01:41) - Tonmya
• (02:32) - Ajovy
• (03:19) - Repatha
• (03:57) - Brinsupri
• (04:26) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app